IN2014CN03919A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03919A
IN2014CN03919A IN3919CHN2014A IN2014CN03919A IN 2014CN03919 A IN2014CN03919 A IN 2014CN03919A IN 3919CHN2014 A IN3919CHN2014 A IN 3919CHN2014A IN 2014CN03919 A IN2014CN03919 A IN 2014CN03919A
Authority
IN
India
Prior art keywords
receptors
pharmaceutical compositions
relates
mineralocorticoid
glucocorticoid
Prior art date
Application number
Other languages
English (en)
Inventor
Jeffrey L Edelman
Alissar Nehme
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47179019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014CN03919(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2014CN03919A publication Critical patent/IN2014CN03919A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN3919CHN2014 2011-11-11 2012-11-09 IN2014CN03919A (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558775P 2011-11-11 2011-11-11
PCT/US2012/064296 WO2013071010A1 (en) 2011-11-11 2012-11-09 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11ß-17-21-TRIOL-3,20-DIONE DERIVATIVES

Publications (1)

Publication Number Publication Date
IN2014CN03919A true IN2014CN03919A (https=) 2015-09-04

Family

ID=47179019

Family Applications (2)

Application Number Title Priority Date Filing Date
IN3903CHN2014 IN2014CN03903A (https=) 2011-11-11 2012-11-09
IN3919CHN2014 IN2014CN03919A (https=) 2011-11-11 2012-11-09

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IN3903CHN2014 IN2014CN03903A (https=) 2011-11-11 2012-11-09

Country Status (24)

Country Link
US (7) US8906892B2 (https=)
EP (2) EP2776041A1 (https=)
JP (2) JP6216719B2 (https=)
KR (2) KR20140095549A (https=)
CN (2) CN104185472B (https=)
AR (1) AR088846A1 (https=)
AU (3) AU2012335590B2 (https=)
BR (2) BR112014011333B1 (https=)
CA (3) CA2855290C (https=)
CL (2) CL2014001243A1 (https=)
CO (2) CO6970598A2 (https=)
ES (1) ES2806603T3 (https=)
HK (1) HK1200366A1 (https=)
IL (2) IL232534A0 (https=)
IN (2) IN2014CN03903A (https=)
MX (3) MX365859B (https=)
MY (2) MY172227A (https=)
PH (2) PH12014501079B1 (https=)
RU (2) RU2688159C2 (https=)
SG (3) SG10201603766PA (https=)
TW (1) TWI584809B (https=)
UA (2) UA116622C2 (https=)
WO (2) WO2013071010A1 (https=)
ZA (2) ZA201403431B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
UA116622C2 (uk) 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
AU2014361790B2 (en) * 2013-12-13 2019-05-23 Allergan, Inc. Polymorphic and amorphous forms of cortisol 17-alpha-benzoate and methods for the preparation and use thereof
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物
KR20170120161A (ko) * 2015-03-05 2017-10-30 알러간, 인코포레이티드 안과용 약물 전달을 위한 자가-유화 약물 전달 시스템(sedds)
CA3037176A1 (en) * 2016-09-16 2018-03-22 Kala Pharmaceuticals, Inc. Particles, compositions, and methods for ophthalmic and/or other applications
WO2019055028A1 (en) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS
CN116023425B (zh) * 2023-03-28 2023-06-20 南京师范大学 曲安西龙衍生物及其医药用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6605514A (https=) * 1966-04-25 1967-10-26
IT1056711B (it) * 1967-04-01 1982-02-20 Vismara F Spa Derivati dell idrocortisone
US3484436A (en) * 1967-09-07 1969-12-16 Syntex Corp Bicyclo(2.2.2)octane - 1 - -carboxylate esters of delta**4 - pregnene corticoid steroids
GB1227992A (https=) 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
US3693032A (en) 1971-04-23 1972-09-19 Ibm Antisaturation technique for ttl circuits
US3984544A (en) * 1975-02-28 1976-10-05 Schering Corporation Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor
JPS52136157A (en) * 1976-04-14 1977-11-14 Taisho Pharmaceut Co Ltd Preparation of steroid 17-esters
JPS60994B2 (ja) * 1976-07-26 1985-01-11 大正製薬株式会社 プレグナン系化合物の17α―エステル類の製造法
DE2735110A1 (de) * 1977-08-04 1979-02-15 Hoechst Ag Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
DE4025342A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
ATE241640T1 (de) * 1999-10-15 2003-06-15 Leo Pharm Prod Ltd Fusidinsäure-derivate
US6395721B1 (en) 2000-01-05 2002-05-28 Leonard Bloom Low potency unpreserved sterile topical corticosteroid compositions for dermatitis
EA011095B1 (ru) * 2002-08-29 2008-12-30 Бёрингер Ингельхайм Фармасьютиклз, Инк. Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
JP2005008596A (ja) * 2003-06-20 2005-01-13 Kobayashi Pharmaceut Co Ltd 眼科用組成物
SI1755616T1 (sl) * 2004-04-08 2014-04-30 Eye Co Pty Ltd. Zdravljenje eksudativne retinopatije z mineralkortikoidi
CA2573668A1 (en) * 2004-07-12 2006-02-16 Allergan, Inc. Ophthalmic compositions and methods for treating ophthalmic conditions
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
PL1864668T3 (pl) * 2006-06-01 2013-04-30 Santen Sas Wykorzystanie proleku do okulistycznego podawania śródszklistkowego
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
JP2009053880A (ja) 2007-08-27 2009-03-12 Sony Broadband Solution Corp 情報処理装置、ならびにcpuユニット
CA2710149A1 (en) * 2007-12-21 2009-07-09 John C. Anthes C20-c21 substituted glucocorticoid receptor agonists
MX379265B (es) * 2008-06-26 2025-03-11 Anterios Inc Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.
UA116622C2 (uk) * 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей

Also Published As

Publication number Publication date
JP2014533275A (ja) 2014-12-11
US8865691B2 (en) 2014-10-21
AR088846A1 (es) 2014-07-10
MX365859B (es) 2019-06-18
CN104185472A (zh) 2014-12-03
JP2014533274A (ja) 2014-12-11
AU2018200436A1 (en) 2018-02-08
BR112014011333A2 (pt) 2017-05-02
AU2012335589A1 (en) 2014-05-29
MY172227A (en) 2019-11-18
US20130123223A1 (en) 2013-05-16
US10188667B2 (en) 2019-01-29
JP6216719B2 (ja) 2017-10-18
KR102049615B1 (ko) 2019-11-28
SG10201603766PA (en) 2016-07-28
CA2855929A1 (en) 2013-05-16
CN104203247A (zh) 2014-12-10
EP2776041A1 (en) 2014-09-17
UA116622C2 (uk) 2018-04-25
EP2776040A1 (en) 2014-09-17
SG11201402247PA (en) 2014-06-27
NZ624920A (en) 2017-06-30
CN104185472B (zh) 2017-06-13
PH12014501078A1 (en) 2014-07-28
CA2991883C (en) 2020-03-10
US20190365786A1 (en) 2019-12-05
AU2018200436B2 (en) 2019-10-24
WO2013071010A1 (en) 2013-05-16
TW201325596A (zh) 2013-07-01
AU2012335590B2 (en) 2017-10-19
PH12014501079A1 (en) 2014-07-28
HK1200367A1 (en) 2015-08-07
BR112014011341A2 (pt) 2017-05-02
RU2014123471A (ru) 2015-12-20
CN104203247B (zh) 2017-06-06
US20130123226A1 (en) 2013-05-16
CO6970598A2 (es) 2014-06-13
IN2014CN03903A (https=) 2015-10-16
WO2013071009A1 (en) 2013-05-16
PH12014501078B1 (en) 2014-07-28
US20180147217A1 (en) 2018-05-31
IL232535B (en) 2019-09-26
MX2014005678A (es) 2014-12-10
US10493082B2 (en) 2019-12-03
CA2991883A1 (en) 2013-05-16
NZ624919A (en) 2016-10-28
RU2688159C2 (ru) 2019-05-20
MX363669B (es) 2019-03-29
US9433631B2 (en) 2016-09-06
EP2776040B1 (en) 2020-04-22
CA2855290C (en) 2017-02-28
MY182222A (en) 2021-01-18
ZA201403431B (en) 2016-05-25
AU2012335590A1 (en) 2014-05-29
BR112014011333B1 (pt) 2020-04-28
US20170182062A1 (en) 2017-06-29
CA2855290A1 (en) 2013-05-16
RU2683775C2 (ru) 2019-04-02
US9717743B2 (en) 2017-08-01
ZA201403430B (en) 2016-05-25
IL232535A0 (en) 2014-06-30
RU2014123472A (ru) 2015-12-20
KR20140095548A (ko) 2014-08-01
TWI584809B (zh) 2017-06-01
CO6970609A2 (es) 2014-06-13
JP6158201B2 (ja) 2017-07-05
US8906892B2 (en) 2014-12-09
AU2012335589B2 (en) 2017-08-31
MX2019006877A (es) 2019-08-22
PH12014501079B1 (en) 2014-07-28
ES2806603T3 (es) 2021-02-18
MX2014005679A (es) 2014-12-10
IL232534A0 (en) 2014-06-30
US20150005519A1 (en) 2015-01-01
UA111867C2 (uk) 2016-06-24
CL2014001244A1 (es) 2014-11-14
KR20140095549A (ko) 2014-08-01
SG11201402225RA (en) 2014-06-27
CL2014001243A1 (es) 2014-11-28
US20150057258A1 (en) 2015-02-26
CA2855929C (en) 2018-03-27
HK1200366A1 (en) 2015-08-07

Similar Documents

Publication Publication Date Title
IN2014CN03919A (https=)
PH12015501737A1 (en) Androgen receptor modulators and uses thereof
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
NZ630967A (en) C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
NZ705213A (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
MY162689A (en) Oxazoline and isoxazoline derivatives as crac modulators
MX374323B (es) Compuestos de heteroarilo y métodos de uso de los mismos.
WO2013038195A3 (en) Pharmaceutical nanoparticle compositions
PH12016501764B1 (en) Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
IN2013MU02370A (https=)
HK1202117A1 (en) Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an so2-containing group as vanilloid receptor ligands
MX2016011900A (es) Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
TN2011000523A1 (en) Chromenone derivatives as trpv3 antagonists
TN2011000518A1 (en) Fused imidazole carboxamides as trpv3 modulators
TN2011000520A1 (en) Chromane derivatives as trpv3 modulators